The benefits of effective antihypertensive treatment were established at least 40 years ago, but despite the availability of more reliable and better-tolerated antihypertensive drugs, the control of blood pressure remains poor in most patients. Long-term antihypertensive efficacy requires treatment that combines reliable 24-hour reduction of blood pressure with good tolerability to facilitate patient compliance.Treatment should also protect against target-organ damage.As the majority of negative cardiovascular effects of angiotensin II are mediated through the angiotensin II type 1 (AT1) receptor, specific blockade of this receptor is a rational approach for achieving these ideals. Several AT1-receptor blockers have been developed that combine antihypertensive efficacy and placebo-like tolerability — the latter being unique in the history of antihypertensive therapy. In experimental animals these drugs prevent or reverse target organ damage in the heart, the vasculature and the kidney. Ongoing large-scale outcome studies are now underway to establish the benefits of AT1-receptor blockade beyond blood pressure control.
Veterans Administration Cooperative Study Group on Antihypertensive Agents.Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967 ; 212: 1028-1034.
2.
Health Survey for England '96.Volume 1. London : The Stationery Office, 1998.
3.
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee.The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med1997;157:2413-2446.
4.
Dickinson CJNeurogenic hypertension: a synthesis and review. London : Chapman and Hall, 1991.
5.
MacMahon S., Rodgers A.The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence in 1994J Vasc Med Biol1993 ; 4: 265-271.
6.
Veterans Administration Cooperative Study Group on Antihypertensive Agents.Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg.JAMA1970; 213: 1143-1152.
7.
Medical Research CouncilWorking Party.MRC trial on treatment of hypertension: principal results. BMJ1985; 291: 97-104.
8.
Dahlöf B., Lindeholm LH, Hansson L. et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet1991; 338: 1281-1284.
9.
SHEP Cooperative Research Group.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1991; 265: 3255-3264.
10.
Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA1996; 276: 1886-1892.
11.
Staessen JA , Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators . Lancet1997; 350: 757-764.
12.
The Heart Outcome Prevention Evaluation Study Investigators.Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. New Engl J Med2000; 342: 145-153.
13.
Guidelines Subcommittee.1999World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens1999;17:151-183.
14.
Hansson L., Zanchetti A., Carruthers G. et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998; 351: 1755-1762.
15.
Taylor Nelson Healthcare: Copyright Cardiomonitor®, 1992.
16.
Burt V.-L,Wheiton P., Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991 . Hypertension1995; 25: 305-313.
17.
Bennett SA, Magnus P.Trends in cardiovascular risk factors in Australia. Results from the National Heart Foundation's Risk Factor Prevalence Study, 1980-1989. Med J Australia1994;161:519-527.
18.
Hosie J., Wiklund I.Managing hypertension in general practice: Can we do better?J Hum Hypertens1995; 9: 515-518.
19.
Isles CG, Walker LM, Beevers GD et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens1986; 4: 141-156.
20.
Jones JK, Gorkin L., Lian JF et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population . BMJ1995; 311: 293-295.
21.
Juilleret L. , Nussberger J., Ménard J. et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension1990;16:564-572.
22.
Urata H., Nishimura H., Ganten D.Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens1996;9:277-284.
23.
Ménard J., Chatellier G.,Azizi M.Do we need angiotensin II antagonists to treat hypertensive patients?J Hum Hypertens1997;11(suppl 2):S1-7.
24.
Israili ZH, Hall WDCough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med1992;117:234-242.
25.
Sunman W., Sever PSNon-angiotensin effects of angiotensin converting enzyme inhibitors . Clin Sci1993; 85: 661-670.
26.
Booz GW, Baker KMRole of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension1996 ; 28: 635-640.
27.
Ford WR, Clanachan AS, Jugdutt BIOpposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation1996; 94: 3087-3089.
28.
Garcha RS, Sever PS, Hughes ADAction of AT1-receptor antagonists on angiotesin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol1999;127(8):1876-82.
29.
Morsing P., Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension1999; 33: 1406-1413.
30.
Vanderheyden PML , Fierens FLP, de Backer JP et al. Distinction between surmountable and insurmountable selective AT1-receptor antagonists by use of CHO-K11 cells expressing human angiotensin II AT1-receptors. Br J Pharmacol1999; 126: 1057-1065.
31.
ChiuAT, Mccall DE, Price WA,Wong PC, Carini DJ, Duncia JV,Wexler RR,Yoo SE, Johnson AL, & Timmermans PBNonpeptide angiotensin II receptor antagonists.VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1990; 252: 711-718.
32.
Corriu C., Bernard S., Schott C. & Stoclet JCEffects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol1995; 26: 688-692.
33.
Noda M., Shibouta Y., Inada Y., Ojima M., Wada T., Sanada T., Kubo K., Kohara Y., Naka T. & Nishikawa K.Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol1993; 46: 311-318.
34.
Chiu,ATMccall D.,Aldrich PE & Timmermans PB[3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype . Biochem Biophys Res Commun1990;172:1195-202.
35.
Chiu AT, Mccall DE, Ardecky RJ, Duncia JV, Nguyen TT & Timmermans PBAngiotensin II receptor subtypes and their selective nonpeptide ligands . Receptor1990;1:33-40.
36.
Wong PC, Hart SD, Zaspel AM, Chiu AT,Ardecky RJ, Smith RD & Timmermans PBFunctional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DUP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther1990; 255: 584-592.
37.
Ojima M., InadaY.,Shibouta Y., Wada T., Sanada T., Kubo K.& Nishikawa K.Candesartan (CV-11974) dissociates slowly from the angiotensin AT -receptor . Eur J Pharmacol1997; 319: 137-146.
38.
Andersson OK , Neldam S.The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist , in comparison with losartan. Blood Pressure1998; 7: 53-59.
39.
Kassler-Taub K., Littlejohn T., Elliott W. et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators . Am J Hypertens1998; 11(4, part 1): 445-453.
40.
Gradman AH, Arcuri KE, Goldberg AI et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension1995; 25: 1345-1350.
41.
Lacourcière Y.,Asmar R., on behalf of the CHAMP study group.Comparison of the impact of missed doses of candesartan and losartan in ambulatory hypertensive patients. Am J Hypertens1999;12(4,part 2): 143A.
42.
Inada Y., Wada T., Ojima M. et al. Protective effects of candesartan cilexetil (TCV116) on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens1997;19:1079-1099.
43.
Mitsunami K. , Inoue S., Maeda K. et al.Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension . Cardiovasc Drugs Ther1998; 12: 469-474.
44.
Kahan T.The importance of left ventricular hypertrophy in human hypertension . J Hypertens Suppl1998;16:S23-S29.
45.
Tedesco MA, Ratti G.,Aquino D. et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens1998; 12: 505-510.
46.
Thurmann PA , Kenedi P., Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension . Circulation1998; 98: 2037-2042.
47.
Fridman K., Andersson OK, Wysocki M., Friberg P.Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol1998;54: 497-501.1.
48.
Fridman K.,Wysocki M., Friberg P.,Andersson O.Long-term effects of candesartan cilexetil on the systemic and renal haemodynamics in moderately hypertensive patients. Am J Hypertens1998;11(4,part 2): 77A.
49.
Forsblom C. , Trenkwalder P., Dahl K. et al. Candesartan cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension. Am J Hypertens1997 ; 10(4, part 2): 86A.
50.
Dahlöf B., Devereux RB, Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension . Hypertension1998; 32: 989-997.
51.
Mann J., Julius S.The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998; 7: 176-183.
52.
Hansson L., Lithell H., Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Pressure1999; 8: 177-183.
53.
Burnier M., Brunner HRAntagonistes des récepteurs AT1 de l'angiotensine II: développement clinique et perspectives futures. [Angiotensin II AT1-receptor antagonists: clinical development and future perspectives.]Therapie1998; 53: 279-284. (French).
54.
Ritz E., Rychlik I., Miltenberger-Miltenyi G.Optimizing antihypertensive therapy in patients with diabetic nephropathy . J Hypertens Suppl1998; 16(7): S17-S22.
